Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-09-21-Speech-2-511"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-09-21"^^xsd:date2
dcterms:Is Part Of	lp_eu:Pharmacovigilance of medicinal products (amendment of Regulation (EC) No 726/2004) - Pharmacovigilance (amendment of Directive 2001/83/EC) (debate)2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20100921.18.2-511"2
lpv:hasSubsequent	lp_eu:2010-09-21-Speech-2-5122
lpv:speaker	lp:Olivier Chastel2
lpv:translated text	"Mr President, ladies and gentlemen, I should like first of all to congratulate Mrs McAvan and the various rapporteurs, as well as the Spanish Presidency and the Commission, on the work done in order to reach this balanced agreement, which is so vital to all European patients. This dossier is, in fact, a specific example of European added value in the lives of our fellow citizens, and the application of these provisions will, no doubt, allow us to revise downwards the number of medical cases caused by adverse drug reactions, a factor which, even today, as we have been reminded here, is one of the main causes of death, especially in hospitals. We have every reason to welcome this vote, at first reading, of these clear and effective new pharmacovigilance rules. I also hope that, by the end of the Belgian Presidency, we shall be able to welcome an agreement on the other dossiers in the pharmaceutical package. The Presidency has, in fact, taken action in collaboration with Parliament and the Commission to advance what are vital dossiers both for our fellow citizens, and European patients in particular, and for the pharmaceutical sector."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph